A large trial of pelacarsen cut lipoprotein(a), or Lp(a), by about 78% within a year but did not reduce major cardiovascular events compared with placebo in patients who already had cardiovascular disease.
Der Spiegel, citing the German Heart Center of Charité, reported that the international study enrolled 8,350 people with elevated Lp(a) and established cardiovascular disease. Participants received monthly pelacarsen injections or placebo.
Over an average 4.7 years, major cardiovascular events, including heart attacks and strokes, occurred in 12.3% of the pelacarsen group and 12.1% of the placebo group, according to the report. The study therefore missed its main clinical goal despite the large reduction in the blood marker.
The result draws a necessary line between changing a biomarker and improving patient outcomes. Elevated Lp(a) remains associated with cardiovascular risk, but this trial found no event reduction from pelacarsen under the conditions studied. It should not be extended to every Lp(a)-targeting approach or to individual treatment decisions.
The supplied report does not include the full statistical analysis, subgroup results or safety data. Those details matter for judging the study and any future clinical implications, but the reported result itself is already consequential: a large fall in Lp(a) did not translate into fewer major cardiovascular events in this trial.
Sources
- Der Spiegel · Source date: 2026-11-12
Independent editorial content. WUA is not affiliated with any political party. 2026-11-12